长城国瑞证券给予华东医药买入评级：核心引擎强劲，创新管线驱动未来

Group 1 - The core viewpoint of the report is a "buy" rating for Huadong Medicine (000963.SZ) based on its strong revenue growth and performance driven by the pharmaceutical industry [2] - The company's revenue has shown steady growth, with innovative product business income surpassing 1 billion yuan, indicating a rapid growth phase [2] - Huadong Medicine has a robust pipeline with over 80 innovative drug research and development projects, focusing on three major therapeutic areas [2] Group 2 - The industrial microbiology segment is experiencing a positive sales trend, contributing to the overall performance of the company [2] - Although the medical beauty business is currently under pressure, there are signs of improvement on a quarter-on-quarter basis [2]